Wall Street also was waiting to see whether President Donald Trump would follow through on his pledge to enact tariffs on ...
Vertex Pharmaceuticals (VRTX – Research Report) received a Buy rating and a $480.00 price target from Cantor Fitzgerald analyst Olivia Brayer ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...
Needham analyst Joseph Stringer has maintained their neutral stance on VRTX stock, giving a Hold rating today.Invest with Confidence: Follow ...
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...